نتایج جستجو برای: refractory nhl lymphoma
تعداد نتایج: 155852 فیلتر نتایج به سال:
A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib was conducted in 93 adult patients with relapsed or refractory lymphoma. Patients received tipifarnib 300 mg twice daily on days 1-21 of each 28-day cycle. The median number of prior therapies was 5 (range, 1-17). For the aggressive B-cell, indolent B-cell, and T-cell and Hodgkin lymphoma (HL/T) groups, the response rates were...
Background: China is facing the aggravating disease burden of lymphoma. However, accurate information about lymphoma at national and provincial levels limited. Methods: Following general analytical strategy used in Global Burden Diseases, Injuries, Risk Factors Study 2019, age-, sex- province-specific incidence, mortality prevalence Hodgkin (HL) non-Hodgkin (NHL) were analyzed. Lymphoma was ass...
Low-grade rash may occur with lenalidomide, rituximab, or their combination (R) in non-Hodgkin lymphoma (NHL). From our phase II study of R in previously untreated indolent lymphoma (n=110), 52 (47%) patients had rash, which was associated with pruritus in 22 (42%). Worst grade 1, 2, and 3 rash was found in 19%, 21%, and 7%, respectively. Grade 1/2 rash was effectively managed with observation,...
Diffuse large B-cell lymphoma (DLBCL) of the heart accounts for only 1% primary cardiac tumors. Histopathologic examination becomes key diagnosis and immunohistochemical evaluation non-Hodgkin (NHL) subtype determination is able to predict disease progression therapeutical modality. Case description: 70-year-old man complained shortness breath. Echocardiographic revealed mass occupied left atri...
A phase II study was undertaken to assess whether continuous infusion of high-dose recombinant interleukin-2 (rlL-2) alone was active against different histologic subtypes of heavily pretreated lymphoma. Sixty one lymphomas were included in the study. rlL-2 (Roussel UCLAF, Romainville, France) was administered by continuous infusion at 20 x lo6 IU/mZ for three cycles of 5 days, 4 days, and 3 da...
BACKGROUND The most common lymphoid malignancy in adults is diffuse large B-cell lymphoma (DLBCL). The median age of occurrence of DLBCL is between 6th and 7th decade of life, although some other types of aggressive non-Hodgkin's lymphomas (NHL) are present in younger age. Primary central nervous system lymphoma (PCNSL) is an uncommon type of extranodal NHL, which is either more prevalent or is...
PURPOSE The incidence of non-Hodgkin's lymphoma (NHL), the fifth most common malignancy in the United States, has increased over 70% in the last 30 years. Fifty percent to 75% of patients with low-grade or follicular NHL respond to rituximab therapy. However, responses are generally of limited duration, and complete responses are rare. Preclinical work suggests that human recombinant interleuki...
INTRODUCTION Non-Hodgkin's lymphoma (NHL) is the sixth most common malignancy, and follicular lymphoma (FL) is the second most common form of NHL. FL is generally considered to be incurable, and is characterized by periods of remission followed by episodes of relapse, with median survival of 8-10 years. Maintenance treatment is aimed at improving quality of life and survival. AIMS To review t...
Molecular targeting therapy has become a relevant therapeutic strategy for cancer. There are several monoclonal antibodies used for the treatment of malignant tumors. Radioimmunoconjugate is composed of antibody and radionuclide showing a synergistic effect of radiation and immunemediated cellular toxicity and thereby enabling increased efficacy and minimizing toxicity. Radioimmunotherapy using...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید